{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T21:02:33Z","timestamp":1781211753664,"version":"3.54.1"},"reference-count":41,"publisher":"Begell House","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Crit Rev Eukaryot Gene Expr"],"published-print":{"date-parts":[[2026]]},"abstract":"<p>&lt;b&gt;Background:&lt;\/b&gt; Pulmonary tuberculosis (PTB) development is linked to dysregulated immune responses, with the innate immune cell barrier playing a crucial role in both disease initiation and progression.\n\n&lt;b&gt;Methods:&lt;\/b&gt; The acquisition of transcriptomic datasets pertaining to PTB was conducted using the GEO database. Modules associated with the innate immune cell barrier were identified using weighted gene co-expression network analysis. The intersection of the differentially expressed genes and the module genes yielded a set of overlapping genes. Biological pathways were characterized and candidate genes were screened through functional enrichment analyses and protein-protein interaction network modeling. Key genes were identified through the application of machine-learning algorithms and further confirmed via qPCR using clinical samples. Diagnostic models were developed and independently evaluated. Multiple analytical approaches were employed to explore the biological mechanisms and therapeutic potential. These included gene set enrichment analysis, immune cell infiltration profiling, regulatory network analysis, and molecular docking.\n\n&lt;b&gt;Results:&lt;\/b&gt; A total of 360 overlapping genes were identified, enriched in immune activation and inflammatory pathways. Nineteen candidates were screened, and five key genes-OAS1, STAT2, IFITM1, CCR7, and CD19-were prioritized through machine learning. qPCR validation confirmed consistent expression trends for all genes except CD19. These genes were enriched in lysosomal and ribosomal pathways, with aberrant neutrophil and monocyte infiltration strongly correlating with gene expression. Molecular docking identified peginterferon-alfa-2a and isotretinoin as potential therapeutic agents.\n\n&lt;b&gt;Conclusion:&lt;\/b&gt; This study identified five key genes and two potential drug candidates associated with innate immune dysregulation in PTB, providing new insights into disease mechanisms and supporting their potential value in PTB diagnosis and therapy.<\/p>","DOI":"10.1615\/critreveukaryotgeneexpr.2026063297","type":"journal-article","created":{"date-parts":[[2026,3,2]],"date-time":"2026-03-02T16:56:51Z","timestamp":1772470611000},"page":"49-64","source":"Crossref","is-referenced-by-count":0,"title":["Exploring Biomarkers and Regulatory Mechanisms Associated with the Innate Immune Cell Barrier in Pulmonary Tuberculosis Using Bioinformatics and Machine Learning"],"prefix":"10.1615","volume":"36","author":[{"given":"Qin","family":"Zhu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheng","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiong","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhengfeng","family":"Hang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"613","reference":[{"key":"2","doi-asserted-by":"crossref","unstructured":"Trajman A, Campbell JR, Kunor T, Ruslami R, Amanullah F, Behr MA, Menzies D. Tuberculosis. Lancet. 2025;405(10481):850-66.","DOI":"10.1016\/S0140-6736(24)02479-6"},{"key":"3","doi-asserted-by":"crossref","unstructured":"Fekadu G, Chow DY, You JHS. The pharmacotherapeutic management of pulmonary tuberculosis: An update of the state-of-the-art. Expert Opin Pharmacother. 2022;23(1):139-48.","DOI":"10.1080\/14656566.2021.1967930"},{"key":"4","unstructured":"World Health Organization (WHO). Global Tuberculosis Report 2024. 2024. Available from: https:\/\/www.who.int\/teams\/global-programme-on-tuberculosis-and-lung-health\/tb-reports\/global-tuberculosis-report-2024."},{"key":"5","unstructured":"Tobin EH, Tristram D. Tuberculosis overview. Treasure Island, FL: StatPearls; 2025."},{"key":"6","doi-asserted-by":"crossref","unstructured":"Bartolomeu-Gon\u00e7alves G, Souza JM, Fernandes BT, Spoladori LFA, Correia GF, Castro IM, Borges PHG, Silva-Rodrigues G, Tavares ER, Yamauchi LM, Pelisson M, Perugini MRE, Yamada-Ogatta SF. Tuberculosis diagnosis: Current, ongoing, and future approaches. Diseases. 2024;12(9).","DOI":"10.3390\/diseases12090202"},{"key":"7","doi-asserted-by":"crossref","unstructured":"Tan ZM, Lai GP, Pandey M, Srichana T, Pichika MR, Gorain B, Bhattamishra SK, Choudhury H. Novel approaches for the treatment of pulmonary tuberculosis. Pharmaceutics. 2020;12(12).","DOI":"10.3390\/pharmaceutics12121196"},{"key":"8","doi-asserted-by":"crossref","unstructured":"Shen L, Liao K, Yang E, Yang F, Lin W, Wang J, Fan S, Huang X, Chen L, Shen H, Jin H, Ruan Y, Liu X, Zeng G, Xu JF, Pi J. Macrophage targeted iron oxide nanodecoys augment innate immunological and drug killings for more effective Mycobacterium tuberculosis clearance. J Nanobiotechnol. 2023;21(1):369.","DOI":"10.1186\/s12951-023-02103-x"},{"key":"9","doi-asserted-by":"crossref","unstructured":"Kaur BP, Secord E. Innate immunity. Immunol Allergy Clin North Am. 2021;41(4):535-41.","DOI":"10.1016\/j.iac.2021.07.003"},{"key":"10","doi-asserted-by":"crossref","unstructured":"Maiorino L, Da\u00dfler-Plenker J, Sun L, Egeblad M. Innate immunity and cancer pathophysiology. Annu Rev Pathol. 2022;17:425-57.","DOI":"10.1146\/annurev-pathmechdis-032221-115501"},{"key":"11","doi-asserted-by":"crossref","unstructured":"Johnston DGW, Kirby B, Tobin DJ. Hidradenitis suppurativa: A folliculotropic disease of innate immune barrier dysfunction? Exp Dermatol. 2021;30(10):1554-68.","DOI":"10.1111\/exd.14451"},{"key":"12","doi-asserted-by":"crossref","unstructured":"Scriba TJ, Maseeme M, Young C, Taylor L, Leslie AJ. Immunopathology in human tuberculosis. Sci Immunol. 2024;9(102):eado5951.","DOI":"10.1126\/sciimmunol.ado5951"},{"key":"13","doi-asserted-by":"crossref","unstructured":"Sankar P, Mishra BB. Early innate cell interactions with Mycobacterium tuberculosis in protection and pathology of tuberculosis. Front Immunol. 2023;14:1260859.","DOI":"10.3389\/fimmu.2023.1260859"},{"key":"14","doi-asserted-by":"crossref","unstructured":"Panda S, Seelan DM, Faisal S, Arora A, Luthra K, Palanichamy JK, Mohan A, Vikram NK, Gupta NK, Ramakrishnan L, Singh A. Chronic hyperglycemia drives alterations in macrophage effector function in pulmonary tuberculosis. Eur J Immunol. 2022;52(10):1595-609.","DOI":"10.1002\/eji.202249839"},{"key":"15","doi-asserted-by":"crossref","unstructured":"Sankar P, Mishra BB. Early innate cell interactions with Mycobacterium tuberculosis in protection and pathology of tuberculosis. Front Immunol. 2023;14:1260859.","DOI":"10.3389\/fimmu.2023.1260859"},{"key":"16","doi-asserted-by":"crossref","unstructured":"Martin-Fernandez M, Bogunovic D. A non-canonical function of OAS1 to combat viral and bacterial infections. Immunity. 2024;57(8):1721-3.","DOI":"10.1016\/j.immuni.2024.07.018"},{"key":"17","doi-asserted-by":"crossref","unstructured":"Qiu Q, Peng A, Zhao Y, Liu D, Liu C, Qiu S, Xu J, Cheng H, Xiong W, Chen Y. Diagnosis of pulmonary tuberculosis via identification of core genes and pathways utilizing blood transcriptional signatures: A multicohort analysis. Respir Res. 2022;23(1):125.","DOI":"10.1186\/s12931-022-02035-4"},{"key":"18","doi-asserted-by":"crossref","unstructured":"Jordan MB. Loss of STAT2 may be dangerous in a world filled with viruses. J Clin Invest. 2023;133(12).","DOI":"10.1172\/JCI170886"},{"key":"19","doi-asserted-by":"crossref","unstructured":"Zhang L, Jiang X, Pfau D, Ling Y, Nathan CF. Type I interferon signaling mediates Mycobacterium tuberculosis-induced macrophage death. J Exp Med. 2021; 218(2).","DOI":"10.1084\/jem.20200887"},{"key":"20","doi-asserted-by":"crossref","unstructured":"G\u00f3mez-Herranz M, Taylor J, Sloan RD. IFITM proteins: Understanding their diverse roles in viral infection, cancer, and immunity. J Biol Chem. 2023;299(1):102741.","DOI":"10.1016\/j.jbc.2022.102741"},{"key":"21","doi-asserted-by":"crossref","unstructured":"Petrilli JD, Ara\u00fajo LE, da Silva LS, Laus AC, M\u00fcller I, Reis RM, Netto EM, Riley LW, Arruda S, Queiroz A. Whole blood mRNA expression-based targets to discriminate active tuberculosis from latent infection and other pulmonary diseases. Sci Rep. 2020;10(1):22072.","DOI":"10.1038\/s41598-020-78793-2"},{"key":"22","doi-asserted-by":"crossref","unstructured":"Hong W, Yang B, He Q, Wang J, Weng Q. New insights of CCR7 signaling in dendritic cell migration and inflammatory diseases. Front Pharmacol. 2022;13:841687.","DOI":"10.3389\/fphar.2022.841687"},{"key":"23","doi-asserted-by":"crossref","unstructured":"Fan J, Yang Y, Wang L, Shang X, Zhang L, Sun H, Ma Y, Li Y, Wang J, Ma X. Study on the correlation between interleukin-27 and CXCL10 in pulmonary tuberculosis. J Immunol Res. 2022;2022:2932837.","DOI":"10.1155\/2022\/2932837"},{"key":"24","doi-asserted-by":"crossref","unstructured":"Komura K. CD19: A promising target for systemic sclerosis. Front Immunol. 2024;15:1454913.","DOI":"10.3389\/fimmu.2024.1454913"},{"key":"25","doi-asserted-by":"crossref","unstructured":"Liu H, Ji S, Fang Y, Yi X, Wu F, Xing F, Wang C, Zhou H, Xu J, Sun W. Microbiome alteration in lung tissues of tuberculosis patients revealed by metagenomic next-generation sequencing and immune-related transcriptional profile identified by transcriptome sequencing. ACS Infect Dis. 2023;9(12):2572-82.","DOI":"10.1021\/acsinfecdis.3c00416"},{"key":"26","doi-asserted-by":"crossref","unstructured":"Stewart P, Patel S, Comer A, Muneer S, Nawaz U, Quann V, Bansal M, Venketaraman V. Role of B cells in mycobacterium tuberculosis infection. Vaccines. 2023;11(5).","DOI":"10.3390\/vaccines11050955"},{"key":"27","doi-asserted-by":"crossref","unstructured":"Alcantara CA, Glassman I, Nguyen KH, Parthasarathy A, Venketaraman V. Neutrophils in Mycobacterium tuberculosis. Vaccines. 2023;11(3).","DOI":"10.3390\/vaccines11030631"},{"key":"28","doi-asserted-by":"crossref","unstructured":"Gern BH, Klas JM, Foster KA, Kanagy ME, Cohen SB, Plumlee CR, Duffy FJ, Neal ML, Halima M, Gustin AT, Stull SM, Wilson JJ, Diercks AH, Aderem A, Gale M, Jr., Aitchison JD, Gerner MY, Urdahl KB. Early and opposing neutrophil and CD4 T cell responses shape pulmonary tuberculosis pathology. J Exp Med. 2025;222(10).","DOI":"10.1084\/jem.20250161"},{"key":"29","doi-asserted-by":"crossref","unstructured":"Pan SW, Shu CC, Huang JR, Lee CC, Tseng YH, Hung JJ, Hsu PK, Chen NJ, Su WJ, Feng JY, Chen YM. PD-L1 expression in monocytes correlates with bacterial burden and treatment outcomes in active pulmonary tuberculosis. Int J Mol Sci. 2022;23(3).","DOI":"10.3390\/ijms23031619"},{"key":"30","doi-asserted-by":"crossref","unstructured":"Ahmad F, Rani A, Alam A, Zarin S, Pandey S, Singh H, Hasnain SE, Ehtesham NZ. Macrophage: A cell with many faces and functions in tuberculosis. Front Immunol. 2022;13:747799.","DOI":"10.3389\/fimmu.2022.747799"},{"key":"31","doi-asserted-by":"crossref","unstructured":"Ufimtseva EG, Eremeeva NI, Umpeleva TV, Vakhrusheva DV, Skornyakov SN. Mycobacterium tuberculosis load in host cells and the antibacterial activity of alveolar macrophages are linked and differentially regulated in various lung lesions of patients with pulmonary tuberculosis. Int J Mol Sci. 2021;22(7).","DOI":"10.3390\/ijms22073452"},{"key":"32","doi-asserted-by":"crossref","unstructured":"Rijnink WF, Ottenhoff THM, Joosten SA. B-Cells and antibodies as contributors to effector immune responses in tuberculosis. Front Immunol. 2021;12:640168.","DOI":"10.3389\/fimmu.2021.640168"},{"key":"33","doi-asserted-by":"crossref","unstructured":"Lu YJ, Barreira-Silva P, Boyce S, Powers J, Cavallo K, Behar SM. CD4 T cell help prevents CD8 T cell exhaustion and promotes control of Mycobacterium tuberculosis infection. Cell Rep. 2021;36(11):109696.","DOI":"10.1016\/j.celrep.2021.109696"},{"key":"34","doi-asserted-by":"crossref","unstructured":"Li S, Wang D, Wei P, Liu R, Guo J, Yang B, Zhang H, Lu J, Gao M, Pang Y. Elevated natural killer cell-mediated cytotoxicity is associated with cavity formation in pulmonary tuberculosis patients. J Immunol Res. 2021;2021:7925903.","DOI":"10.1155\/2021\/7925903"},{"key":"35","doi-asserted-by":"crossref","unstructured":"Kim H, Shin SJ. Pathological and protective roles of dendritic cells in Mycobacterium tuberculosis infection: Interaction between host immune responses and pathogen evasion. Front Cell Infect Microbiol. 2022;12:891878.","DOI":"10.3389\/fcimb.2022.891878"},{"key":"36","doi-asserted-by":"crossref","unstructured":"Maio M, Barros J, Joly M, Vahlas Z, Mar\u00edn Franco JL, Genoula M, Monard SC, Vecchione MB, Fuentes F, Gonzalez Polo V, Quiroga MF, Vermeulen M, Vu Manh TP, Arg\u00fcello RJ, Inwentarz S, Musella R, Ciallella L, Gonz\u00e1lez Montaner P, Palmero D, Lugo Villarino G, Sasiain MDC, Neyrolles O, V\u00e9rollet C, Balboa L. Elevated glycolytic metabolism of monocytes limits the generation of HIF1A-driven migratory dendritic cells in tuberculosis. Elife. 2024;12.","DOI":"10.7554\/eLife.89319.4"},{"key":"37","doi-asserted-by":"crossref","unstructured":"Armani-Tourret M, Gao C, Hartana CA, Sun W, Carrere L, Vela L, Hochroth A, Bellefroid M, Sbrolla A, Shea K, Flynn T, Roseto I, Rassadkina Y, Lee C, Giguel F, Malhotra R, Bushman FD, Gandhi RT, Yu XG, Kuritzkes DR, Lichterfeld M. Selection of epigenetically privileged HIV-1 proviruses during treatment with panobinostat and interferon-\u00ce\u00b12a. Cell. 2024;187(5):1238-54.","DOI":"10.1016\/j.cell.2024.01.037"},{"key":"38","doi-asserted-by":"crossref","unstructured":"Park J, Han J, Chung TY, Lim DH, Choi CY. Pegylated interferon Alpha 2a for the treatment of ocular surface squamous neoplasia. Cornea. 2022;41(10):1271-5.","DOI":"10.1097\/ICO.0000000000003086"},{"key":"39","doi-asserted-by":"crossref","unstructured":"Gosmann J, Stadler R, Quint KD, Gutzmer R, Vermeer MH. Use of pegylated interferon Alpha-2a in cutaneous T-cell lymphoma: A retrospective case collection. Acta Derm Venereol. 2023;103:adv10306.","DOI":"10.2340\/actadv.v103.10306"},{"key":"40","doi-asserted-by":"crossref","unstructured":"Ferenczi K, Nagy ZF, Istenes I, Eid H, B\u00f6d\u00f6r C, Tim\u00e1r B, Demeter J. Successful treatment of hairy cell leukaemia with pegylated interferon-alpha-2A. Pathol Oncol Res. 2025;31:1612108.","DOI":"10.3389\/pore.2025.1612108"},{"key":"41","doi-asserted-by":"crossref","unstructured":"Kapa\u0142a J, Lewandowska J, Placek W, Owczarczyk-Saczonek A. Adverse events in isotretinoin therapy: A single-arm meta-analysis. Int J Environ Res Public Health. 2022;19(11).","DOI":"10.3390\/ijerph19116463"},{"key":"42","doi-asserted-by":"crossref","unstructured":"Howard JN, Levinger C, Deletsu S, Fromentin R, Chomont N, Bosque A. Isotretinoin promotes elimination of translation-competent HIV latent reservoirs in CD4T cells. PLoS Pathog. 2024;20(10):e1012601.","DOI":"10.1371\/journal.ppat.1012601"}],"container-title":["Critical Reviews in Eukaryotic Gene Expression"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.dl.begellhouse.com\/download\/article\/5357977a68a60d67\/CRE-63297.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T20:05:10Z","timestamp":1781208310000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.dl.begellhouse.com\/journals\/6dbf508d3b17c437,1b3ca8ea32a138e3,5357977a68a60d67.html"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026]]},"references-count":41,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1615\/critreveukaryotgeneexpr.2026063297","relation":{},"ISSN":["1045-4403"],"issn-type":[{"value":"1045-4403","type":"print"}],"subject":[],"published":{"date-parts":[[2026]]}}}